KR100459984B1 - 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드 - Google Patents

에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드 Download PDF

Info

Publication number: KR100459984B1
Authority: KR; South Korea
Prior art keywords: peptide; epo; amino acid; peptides; amino acids
Prior art date: 1995-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

KR1019970709231A

Other languages

English (en)

Korean (ko)

Other versions

KR19990022656A (ko

Inventor

씨. 라이튼 니콜라스

제이. 도워 윌리엄

에스. 창 레이

케이. 케쉬얍 아런

케이. 졸리프 린다

존슨 다나

멀케히 린다

Original Assignee

아피맥스 테크놀로지스, 엔.브이.

오르토 파마슈티칼 코오포레이숀

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

2005-06-20

1995-06-07 Priority claimed from US08/484,635 external-priority patent/US5773569A/en

1995-06-07 Priority claimed from US08/484,631 external-priority patent/US5830851A/en

1996-06-07 Application filed by 아피맥스 테크놀로지스, 엔.브이., 오르토 파마슈티칼 코오포레이숀 filed Critical 아피맥스 테크놀로지스, 엔.브이.

1999-03-25 Publication of KR19990022656A publication Critical patent/KR19990022656A/ko

2005-06-20 Application granted granted Critical

2005-06-20 Publication of KR100459984B1 publication Critical patent/KR100459984B1/ko

2016-06-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

KR1019970709231A 1995-06-07 1996-06-07 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드 Expired - Fee Related KR100459984B1 (ko)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US08/484,635 US5773569A (en)	1993-11-19	1995-06-07	Compounds and peptides that bind to the erythropoietin receptor
US08/484,631 US5830851A (en)	1993-11-19	1995-06-07	Methods of administering peptides that bind to the erythropoietin receptor
US08/484635		1995-06-07
US8/484631		1995-06-07
US08/484631		1995-06-07
US8/484635		1995-06-07

Publications (2)

Publication Number	Publication Date
KR19990022656A KR19990022656A (ko)	1999-03-25
KR100459984B1 true KR100459984B1 (ko)	2005-06-20

Family

ID=27048076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019970709231A Expired - Fee Related KR100459984B1 (ko)	1995-06-07	1996-06-07	에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드

Country Status (18)

Country	Link
EP (2)	EP0886648B8 (fr)
JP (3)	JP4050314B2 (fr)
KR (1)	KR100459984B1 (fr)
CN (1)	CN1192748A (fr)
AT (1)	ATE254138T1 (fr)
AU (1)	AU712713B2 (fr)
BR (1)	BR9609006A (fr)
CA (1)	CA2223833C (fr)
CZ (1)	CZ391097A3 (fr)
DE (1)	DE69630708T2 (fr)
ES (1)	ES2210374T3 (fr)
HU (1)	HUP9901069A2 (fr)
IL (1)	IL122417A0 (fr)
NO (1)	NO318783B1 (fr)
NZ (1)	NZ310804A (fr)
PL (1)	PL185040B1 (fr)
TR (1)	TR199701557T2 (fr)
WO (1)	WO1996040749A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830851A (en) *	1993-11-19	1998-11-03	Affymax Technologies N.V.	Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) *	1993-11-19	1998-06-30	Affymax Technologies N.V.	Compounds and peptides that bind to the erythropoietin receptor
US5767078A (en) *	1995-06-07	1998-06-16	Johnson; Dana L.	Agonist peptide dimers
US6121416A (en) *	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
DE19904396A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Substituierte Pyrazolbenzylamin-Derivate
DE19904406A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Substituierte Pyrazolcarbonsäuren
US6713309B1 (en)	1999-07-30	2004-03-30	Large Scale Proteomics Corporation	Microarrays and their manufacture
US7179638B2 (en)	1999-07-30	2007-02-20	Large Scale Biology Corporation	Microarrays and their manufacture by slicing
US6703480B1 (en)	1999-11-24	2004-03-09	Palani Balu	Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7259146B2 (en)	2000-05-26	2007-08-21	Ortho-Mcneil Pharmaceutical, Inc.	Neuroprotective peptides
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
EP1581260B1 (fr)	2002-12-31	2014-09-17	Nektar Therapeutics	Reactifs polymeres comprenant une cetone ou un groupe fonctionnel apparente
NZ543935A (en)	2003-05-12	2008-06-30	Affymax Inc	Peptides that bind to the erythropoietin receptor
JP2007500218A (ja)	2003-05-12	2007-01-11	アフィーマックス・インコーポレイテッド	ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
SG160224A1 (en)	2003-05-12	2010-04-29	Affymax Inc	Novel peptides that bind to the erythropoietin receptor
CN1820024B (zh)	2003-05-12	2011-06-22	阿费麦克斯公司	新的聚(乙二醇)修饰的化合物及其用途
US7887789B2 (en)	2003-05-23	2011-02-15	Nektar Therapeutics	Polymer derivatives having particular atom arrangements
WO2005028539A2 (fr)	2003-09-17	2005-03-31	Nektar Therapeutics Al, Corporation	Promedicaments a base de polymere a branches multiples
EA018427B1 (ru)	2003-12-16	2013-07-30	Нектар Терапьютикс	Химически модифицированный налоксон
DE602005012575D1 (en) *	2004-03-17	2009-03-19	Aplagen Gmbh	Isostere transformation
US8562965B2 (en)	2004-05-03	2013-10-22	Nektar Therapeutics	Polymer derivatives comprising an acetal or ketal branching point
WO2005107815A2 (fr)	2004-05-03	2005-11-17	Nektar Therapeutics Al, Corporation	Dérivés de polymères comprenant un point de ramification de type imide
AU2005303887A1 (en) *	2004-11-10	2006-05-18	Aplagen Gmbh	Molecules which promote hematopoiesis
US7589063B2 (en)	2004-12-14	2009-09-15	Aplagen Gmbh	Molecules which promote hematopoiesis
WO2006060148A2 (fr) *	2004-11-11	2006-06-08	Affymax, Inc.	Nouveaux peptides qui se lient au recepteur d'erythropoietine
CN101198321A (zh) *	2005-04-26	2008-06-11	味之素株式会社	骨髓祖红细胞分化诱导剂
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
EA200800109A1 (ru) *	2005-06-23	2008-06-30	Аплаген Гмбх	Суправалентные соединения
EP2371855B1 (fr) *	2005-08-05	2015-07-22	Araim Pharmaceuticals, Inc.	Peptides protecteurs de tissus et utilisations associées
CA2680228A1 (fr) *	2006-03-09	2007-09-13	Aplagen Gmbh	Molecules modifiees destinees a promouvoir l'hematopoiese
US8470963B2 (en)	2006-06-30	2013-06-25	Sku Asset Management Gmbh	Multifunctional compounds for pharmaceutical purposes
WO2008095004A2 (fr)	2007-01-31	2008-08-07	Affymax, Inc.	Groupements de liaison à base d'azote destinés à attacher des groupements modificateurs à des polypeptides et autres macromolécules
EP2018835B1 (fr)	2007-07-09	2014-03-05	Augustinus Bader	Pavé sortant d'agent actif
CN101456911A (zh) *	2007-12-12	2009-06-17	江苏豪森药业股份有限公司	促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
WO2009142679A2 (fr) *	2008-03-26	2009-11-26	Orthologic Corp.	Procédés permettant de traiter un infarctus du myocarde aigu
US8575102B2 (en)	2008-08-01	2013-11-05	Nektar Therapeutics	Conjugates having a releasable linkage
KR101671537B1 (ko)	2008-08-11	2016-11-01	넥타르 테라퓨틱스	다분지형 중합체 알카노에이트 컨쥬게이트
EP2331139B1 (fr)	2008-09-11	2019-04-17	Nektar Therapeutics	Réactifs polymères alpha-hydroxy aldéhydiques et cétoniques et procédé de conjugaison
MX2011003117A (es)	2008-09-19	2011-04-21	Nektar Therapeutics	Conjugados polimericos de peptidos terapeuticos.
WO2010036964A2 (fr) *	2008-09-26	2010-04-01	Ambrx Inc.	Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
JP6059014B2 (ja) *	2009-06-19	2017-01-11	アリゾナボードオブリージェンツアボディーコーポレートアクティングオンビハーフオブアリゾナステイトユニバーシティＡＲＩＺＯＮＡＢＯＡＲＤＯＦＲＥＧＥＮＴＳ，ａｂｏｄｙｃｏｒｐｏｒａｔｅａｃｔｉｎｇｏｎｂｅｈａｌｆｏｆＡＲＩＺＯＮＡＳＴＡＴＥＵＮＩＶＥＲＳＩＴＹ	試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ
WO2011012306A2 (fr)	2009-07-30	2011-02-03	Aplagen Gmbh	Utilisation d'emp pour contrer les effets stimulants de l'epo sur des tumeurs sensibles à l'epo, tout en maintenant l'érythropoïèse
ES2632164T3 (es)	2010-07-06	2017-09-11	Augustinus Bader	Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
WO2012088422A1 (fr)	2010-12-22	2012-06-28	Nektar Therapeutics	Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane
WO2012088445A1 (fr)	2010-12-22	2012-06-28	Nektar Therapeutics	Conjugués promédicaments polymères à plusieurs bras de composés à base de cabazitaxel
WO2012166555A1 (fr)	2011-05-27	2012-12-06	Nektar Therapeutics	Composés à base de médicament et de fraction de liaison liée à un polymère soluble dans l'eau
WO2013171810A1 (fr)	2012-05-14	2013-11-21	パナソニック株式会社	Procédé d'obtention d'un phage présentateur d'anticorps thermorésistant
CN103450348B (zh) *	2012-05-29	2016-03-30	中国人民解放军军事医学科学院毒物药物研究所	一种促红细胞生成素模拟肽、其制备方法和用途
CN106608906A (zh) *	2015-10-22	2017-05-03	天津药物研究院有限公司	一种具有刺激红细胞生成功能的环形多肽的制备及其应用
CN106928338A (zh) *	2015-12-31	2017-07-07	杭州阿德莱诺泰制药技术有限公司	促红细胞生成素肽及衍生物和聚合物、制备方法和应用
GB201609083D0 (en)	2016-05-24	2016-07-06	Syntab Therapeutics Gmbh	Synthetic compound
JP7445978B2 (ja) *	2018-09-14	2024-03-08	エポメッド株式会社	抗エリスロポエチン受容体ペプチド
AU2020292266A1 (en)	2019-06-10	2022-01-27	Respira Therapeutics, Inc.	Carrier-based formulations and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990008822A1 (fr) *	1989-02-03	1990-08-09	Genetics Institute, Inc.	Recepteur d'erythropoietine
US5106954A (en) *	1989-07-26	1992-04-21	Behringwerke Aktiengesellschaft	Erythropoietin (epo) peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5767078A (en) *	1995-06-07	1998-06-16	Johnson; Dana L.	Agonist peptide dimers

1996
- 1996-06-07 NZ NZ310804A patent/NZ310804A/xx not_active IP Right Cessation
- 1996-06-07 HU HU9901069A patent/HUP9901069A2/hu unknown
- 1996-06-07 EP EP96919296A patent/EP0886648B8/fr not_active Expired - Lifetime
- 1996-06-07 EP EP03025811A patent/EP1510524A3/fr not_active Withdrawn
- 1996-06-07 WO PCT/US1996/009810 patent/WO1996040749A1/fr active IP Right Grant
- 1996-06-07 AU AU61667/96A patent/AU712713B2/en not_active Ceased
- 1996-06-07 DE DE69630708T patent/DE69630708T2/de not_active Expired - Lifetime
- 1996-06-07 CZ CZ973910A patent/CZ391097A3/cs unknown
- 1996-06-07 IL IL12241796A patent/IL122417A0/xx unknown
- 1996-06-07 CN CN96196094A patent/CN1192748A/zh active Pending
- 1996-06-07 ES ES96919296T patent/ES2210374T3/es not_active Expired - Lifetime
- 1996-06-07 CA CA2223833A patent/CA2223833C/fr not_active Expired - Fee Related
- 1996-06-07 AT AT96919296T patent/ATE254138T1/de not_active IP Right Cessation
- 1996-06-07 JP JP50202397A patent/JP4050314B2/ja not_active Expired - Fee Related
- 1996-06-07 TR TR97/01557T patent/TR199701557T2/xx unknown
- 1996-06-07 KR KR1019970709231A patent/KR100459984B1/ko not_active Expired - Fee Related
- 1996-06-07 PL PL96323858A patent/PL185040B1/pl not_active IP Right Cessation
- 1996-06-07 BR BR9609006-5A patent/BR9609006A/pt unknown
1997
- 1997-12-05 NO NO19975729A patent/NO318783B1/no not_active IP Right Cessation
2007
- 2007-07-18 JP JP2007186814A patent/JP2007277264A/ja active Pending
2009
- 2009-08-31 JP JP2009200615A patent/JP2009280616A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990008822A1 (fr) *	1989-02-03	1990-08-09	Genetics Institute, Inc.	Recepteur d'erythropoietine
US5106954A (en) *	1989-07-26	1992-04-21	Behringwerke Aktiengesellschaft	Erythropoietin (epo) peptides

Also Published As

Publication number	Publication date
DE69630708D1 (de)	2003-12-18
AU6166796A (en)	1996-12-30
BR9609006A (pt)	1999-12-14
JPH11507367A (ja)	1999-06-29
CA2223833A1 (fr)	1996-12-19
EP0886648A4 (fr)	2000-01-12
KR19990022656A (ko)	1999-03-25
PL323858A1 (en)	1998-04-27
JP2007277264A (ja)	2007-10-25
AU712713B2 (en)	1999-11-11
NZ310804A (en)	1998-10-28
ATE254138T1 (de)	2003-11-15
NO975729D0 (no)	1997-12-05
EP1510524A2 (fr)	2005-03-02
PL185040B1 (pl)	2003-02-28
CA2223833C (fr)	2010-12-21
EP0886648B8 (fr)	2004-03-03
JP4050314B2 (ja)	2008-02-20
ES2210374T3 (es)	2004-07-01
EP1510524A3 (fr)	2006-06-07
DE69630708T2 (de)	2004-08-05
NO975729L (no)	1998-02-05
EP0886648B1 (fr)	2003-11-12
NO318783B1 (no)	2005-05-09
JP2009280616A (ja)	2009-12-03
CN1192748A (zh)	1998-09-09
HUP9901069A2 (hu)	1999-07-28
EP0886648A1 (fr)	1998-12-30
WO1996040749A1 (fr)	1996-12-19
CZ391097A3 (cs)	1998-07-15
TR199701557T2 (xx)	2002-06-21
IL122417A0 (en)	1998-06-15

Publication	Publication Date	Title
KR100459984B1 (ko)	2005-06-20	에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드
US5830851A (en)	1998-11-03	Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en)	1998-06-30	Compounds and peptides that bind to the erythropoietin receptor
AU2004238868B2 (en)	2010-01-21	Peptides that bind to the erythropoietin receptor
AU2004238870B2 (en)	2009-12-17	Novel peptides that bind to the erythropoietin receptor
US20130012685A1 (en)	2013-01-10	Novel peptides that bind to the erythropoietin receptor
US20120157660A1 (en)	2012-06-21	Novel peptides that bind to the erythropoietin receptor
HK1088906B (en)	2012-12-21	Peptides that bind to the erythropoietin receptor

Legal Events

Date	Code	Title	Description
1997-12-06	PA0105	International application	St.27 status event code: A-0-1-A10-A15-nap-PA0105
1997-12-09	R17-X000	Change to representative recorded	St.27 status event code: A-3-3-R10-R17-oth-X000
1999-03-25	PG1501	Laying open of application	St.27 status event code: A-1-1-Q10-Q12-nap-PG1501
2001-06-07	A201	Request for examination
2001-06-07	P11-X000	Amendment of application requested	St.27 status event code: A-2-2-P10-P11-nap-X000
2001-06-07	P13-X000	Application amended	St.27 status event code: A-2-2-P10-P13-nap-X000
2001-06-07	PA0201	Request for examination	St.27 status event code: A-1-2-D10-D11-exm-PA0201
2003-11-26	E902	Notification of reason for refusal
2003-11-26	PE0902	Notice of grounds for rejection	St.27 status event code: A-1-2-D10-D21-exm-PE0902
2004-01-26	R17-X000	Change to representative recorded	St.27 status event code: A-3-3-R10-R17-oth-X000
2004-01-26	T11-X000	Administrative time limit extension requested	St.27 status event code: U-3-3-T10-T11-oth-X000
2004-02-26	T11-X000	Administrative time limit extension requested	St.27 status event code: U-3-3-T10-T11-oth-X000
2004-03-26	T11-X000	Administrative time limit extension requested	St.27 status event code: U-3-3-T10-T11-oth-X000
2004-04-26	T11-X000	Administrative time limit extension requested	St.27 status event code: U-3-3-T10-T11-oth-X000
2004-05-27	P11-X000	Amendment of application requested	St.27 status event code: A-2-2-P10-P11-nap-X000
2004-05-27	P13-X000	Application amended	St.27 status event code: A-2-2-P10-P13-nap-X000
2004-08-25	E701	Decision to grant or registration of patent right
2004-08-25	PE0701	Decision of registration	St.27 status event code: A-1-2-D10-D22-exm-PE0701
2004-11-25	GRNT	Written decision to grant
2004-11-25	PR0701	Registration of establishment	St.27 status event code: A-2-4-F10-F11-exm-PR0701
2004-11-26	PR1002	Payment of registration fee	St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1
2005-06-20	PG1601	Publication of registration	St.27 status event code: A-4-4-Q10-Q13-nap-PG1601
2007-11-21	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4
2008-11-26	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5
2009-12-07	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6
2010-11-19	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7
2011-11-02	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8
2012-10-31	FPAY	Annual fee payment	Payment date: 20121031 Year of fee payment: 9
2012-10-31	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9
2013-10-31	FPAY	Annual fee payment	Payment date: 20131031 Year of fee payment: 10
2013-10-31	PR1001	Payment of annual fee	St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10
2014-11-26	LAPS	Lapse due to unpaid annual fee
2014-11-26	PC1903	Unpaid annual fee	St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20141126 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE
2015-10-09	PC1903	Unpaid annual fee	St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20141126